Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. (June 2012)

• Record Type: Journal Article
• Authors: McEvoy, Linda K; Brewer, James B
• Is Part Of: Imaging in medicine. Volume 4:Number 3(2012)
• Page Start: 343
• Page End: 357
• Publication Date: 2012-06
• Subjects: Alzheimer's disease -- amyloid imaging -- biomarker -- florbetapir -- MCI -- mild cognitive impairment -- MRI -- PET; Diagnostic imaging -- Periodicals; 616.075405
• DOI: 10.2217/iim.12.27
• Languages: English
• ISSNs: 1755-5205

Abstract

The number of elderly patients seeking clinical treatment for memory problems will rise sharply in coming years as our population ages. These patients present a challenge for diagnosis and prognosis since cognitive problems in older patients can arise from many etiologies, some of which are curable. With the development of clinically available biomarkers for detecting Alzheimer's disease pathology in living patients, evaluation of cognitively impaired elderly patients is about to undergo a major paradigm shift. This article describes the two classes of biomarkers available for assessing Alzheimer's disease risk: those that indicate presence of amyloid pathology and those that provide evidence of neuronal injury and neurodegeneration. We argue that, currently, incorporation of biomarkers of neurodegeneration can help in patient prognosis whereas tests for amyloid, if used in isolation, have potential for harm. Amyloid tests are clinically useful only when evidence suggests progressive cognitive decline or neurodegeneration.